Captopril attenuates TAC-induced heart failure via inhibiting Wnt3a/β-catenin and Jak2/Stat3 pathways

Captopril (Cap) as angiotensin-converting enzyme inhibitor (ACEi) is commonly used to treat hypertension and some types of congestive heart failure. However, few studies reported on whether Cap exerts a protective effect on myocardial apoptosis induced by transverse aortic constriction (TAC). This s...

Full description

Bibliographic Details
Main Authors: Yu Zhang, Ling Zhang, Xiaoxue Fan, Weiwei Yang, Boyang Yu, Junping Kou, Fang Li
Format: Article
Language:English
Published: Elsevier 2019-05-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332218386645
id doaj-0359a7f5b14c4cb396254bd9552d7b3c
record_format Article
spelling doaj-0359a7f5b14c4cb396254bd9552d7b3c2021-05-20T07:37:18ZengElsevierBiomedicine & Pharmacotherapy0753-33222019-05-01113Captopril attenuates TAC-induced heart failure via inhibiting Wnt3a/β-catenin and Jak2/Stat3 pathwaysYu Zhang0Ling Zhang1Xiaoxue Fan2Weiwei Yang3Boyang Yu4Junping Kou5Fang Li6Jiangsu Key Laboratory of TCM Evaluation and Translational Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, ChinaJiangsu Key Laboratory of TCM Evaluation and Translational Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, ChinaJiangsu Key Laboratory of TCM Evaluation and Translational Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, ChinaJiangsu Key Laboratory of TCM Evaluation and Translational Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, ChinaJiangsu Key Laboratory of TCM Evaluation and Translational Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, ChinaCorresponding authors at: Jiangsu Key Laboratory of TCM Evaluation and Translational Research, China Pharmaceutical University, 639 Longmian Road, Nanjing, 211198, PR China.; Jiangsu Key Laboratory of TCM Evaluation and Translational Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, ChinaCorresponding authors at: Jiangsu Key Laboratory of TCM Evaluation and Translational Research, China Pharmaceutical University, 639 Longmian Road, Nanjing, 211198, PR China.; Jiangsu Key Laboratory of TCM Evaluation and Translational Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, ChinaCaptopril (Cap) as angiotensin-converting enzyme inhibitor (ACEi) is commonly used to treat hypertension and some types of congestive heart failure. However, few studies reported on whether Cap exerts a protective effect on myocardial apoptosis induced by transverse aortic constriction (TAC). This study aimed at investigating the possible mechanism of Cap on myocardial apoptosis induced by pressure overload. Results showed that Cap significantly decreased heart-to-body weight ratios (HBWR). Cap markedly improved cardiac function, and reduced inner diameter of ascending aorta (Asc Ao) in TAC mice as shown by echocardiography. Enzyme-linked immunosorbent assay (ELISA) results demonstrated that Cap treatment also markedly decreased the level of N-terminal pro-B-type natriuretic peptide (NT-proBNP), atrial natriuretic peptide (ANP), tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6). Cardiac pathological changes and fibrosis have been improved after Cap treatment as shown by hematoxylin-eosin (H&E) staining and Masson’s trichrome staining. Moreover, Terminal deoxynucleotidyl transferase-mediated dexoxyuridine triphosphate nick-end labeling (TUNEL) staining result indicated Cap treatment also significantly inhibited cardiac apoptosis. Western Blot results showed that Cap obviously decreased the expression of cleaved capase-3, Bax, phosphorylated Jak2 (p-Jak2), phosphorylated Stat3 (p-Stat3), Wnt3a and β-catenin proteins, as well as increased Bcl-2 expression. In conclusion, Cap showed a protective effect on TAC-induced cardiac apoptosis, which could be attributed to the inhibition of Wnt3a/β-catenin signaling pathway. Cap also attenuated myocardial hypertrophy induced by TAC via suppression of Jak2/Stat3 pathway.http://www.sciencedirect.com/science/article/pii/S0753332218386645CaptoprilTransverse aortic constrictionApoptosisHypertrophyWnt3a/β-cateninJak2/Stat3
collection DOAJ
language English
format Article
sources DOAJ
author Yu Zhang
Ling Zhang
Xiaoxue Fan
Weiwei Yang
Boyang Yu
Junping Kou
Fang Li
spellingShingle Yu Zhang
Ling Zhang
Xiaoxue Fan
Weiwei Yang
Boyang Yu
Junping Kou
Fang Li
Captopril attenuates TAC-induced heart failure via inhibiting Wnt3a/β-catenin and Jak2/Stat3 pathways
Biomedicine & Pharmacotherapy
Captopril
Transverse aortic constriction
Apoptosis
Hypertrophy
Wnt3a/β-catenin
Jak2/Stat3
author_facet Yu Zhang
Ling Zhang
Xiaoxue Fan
Weiwei Yang
Boyang Yu
Junping Kou
Fang Li
author_sort Yu Zhang
title Captopril attenuates TAC-induced heart failure via inhibiting Wnt3a/β-catenin and Jak2/Stat3 pathways
title_short Captopril attenuates TAC-induced heart failure via inhibiting Wnt3a/β-catenin and Jak2/Stat3 pathways
title_full Captopril attenuates TAC-induced heart failure via inhibiting Wnt3a/β-catenin and Jak2/Stat3 pathways
title_fullStr Captopril attenuates TAC-induced heart failure via inhibiting Wnt3a/β-catenin and Jak2/Stat3 pathways
title_full_unstemmed Captopril attenuates TAC-induced heart failure via inhibiting Wnt3a/β-catenin and Jak2/Stat3 pathways
title_sort captopril attenuates tac-induced heart failure via inhibiting wnt3a/β-catenin and jak2/stat3 pathways
publisher Elsevier
series Biomedicine & Pharmacotherapy
issn 0753-3322
publishDate 2019-05-01
description Captopril (Cap) as angiotensin-converting enzyme inhibitor (ACEi) is commonly used to treat hypertension and some types of congestive heart failure. However, few studies reported on whether Cap exerts a protective effect on myocardial apoptosis induced by transverse aortic constriction (TAC). This study aimed at investigating the possible mechanism of Cap on myocardial apoptosis induced by pressure overload. Results showed that Cap significantly decreased heart-to-body weight ratios (HBWR). Cap markedly improved cardiac function, and reduced inner diameter of ascending aorta (Asc Ao) in TAC mice as shown by echocardiography. Enzyme-linked immunosorbent assay (ELISA) results demonstrated that Cap treatment also markedly decreased the level of N-terminal pro-B-type natriuretic peptide (NT-proBNP), atrial natriuretic peptide (ANP), tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6). Cardiac pathological changes and fibrosis have been improved after Cap treatment as shown by hematoxylin-eosin (H&E) staining and Masson’s trichrome staining. Moreover, Terminal deoxynucleotidyl transferase-mediated dexoxyuridine triphosphate nick-end labeling (TUNEL) staining result indicated Cap treatment also significantly inhibited cardiac apoptosis. Western Blot results showed that Cap obviously decreased the expression of cleaved capase-3, Bax, phosphorylated Jak2 (p-Jak2), phosphorylated Stat3 (p-Stat3), Wnt3a and β-catenin proteins, as well as increased Bcl-2 expression. In conclusion, Cap showed a protective effect on TAC-induced cardiac apoptosis, which could be attributed to the inhibition of Wnt3a/β-catenin signaling pathway. Cap also attenuated myocardial hypertrophy induced by TAC via suppression of Jak2/Stat3 pathway.
topic Captopril
Transverse aortic constriction
Apoptosis
Hypertrophy
Wnt3a/β-catenin
Jak2/Stat3
url http://www.sciencedirect.com/science/article/pii/S0753332218386645
work_keys_str_mv AT yuzhang captoprilattenuatestacinducedheartfailureviainhibitingwnt3abcateninandjak2stat3pathways
AT lingzhang captoprilattenuatestacinducedheartfailureviainhibitingwnt3abcateninandjak2stat3pathways
AT xiaoxuefan captoprilattenuatestacinducedheartfailureviainhibitingwnt3abcateninandjak2stat3pathways
AT weiweiyang captoprilattenuatestacinducedheartfailureviainhibitingwnt3abcateninandjak2stat3pathways
AT boyangyu captoprilattenuatestacinducedheartfailureviainhibitingwnt3abcateninandjak2stat3pathways
AT junpingkou captoprilattenuatestacinducedheartfailureviainhibitingwnt3abcateninandjak2stat3pathways
AT fangli captoprilattenuatestacinducedheartfailureviainhibitingwnt3abcateninandjak2stat3pathways
_version_ 1721435404855410688